Potassium salt of S-omeprazole

Details Potassium salt of S-omeprazole Potassium salt of S-omeprazole

2002-02-14

2004-01-13

Fan, Jane (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S338000

Reexamination Certificate

active

06677455

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1
H
-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to intermediates used in the process, and their preparation.
BACKGROUND OF THE INVENTION AND PRIOR ART
The compound 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1
H
-benzimidazole, having the generic name omeprazole, and therapeutically acceptable salts thereof, are described in EP 5129. The specific alkaline salts of omeprazole are disclosed in EP 124 495. Omeprazole is a proton pump inhibitor, i.e. effective in inhibiting gastric acid secretion, and is useful as an antiulcer agent. In a more general sense, omeprazole may be used for prevention and treatment of gastric-acid related diseases in mammals and especially in man.
Omeprazole is a sulfoxide and a chiral compound, wherein the sulfur atom being the stereogenic center. Thus, omeprazole is a racemic mixture of its two single enantiomers, the R and S-enantiomer of omeprazole, herein referred to as R-omeprazole and S-omeprazole. The absolute configurations of the enantiomers of omeprazole have been determined by an X-ray study of an N-alkylated derivative of the (+)-enantiomer in non-salt form. The (+)-enantiomer of the non-salt form and the (−)-enantiomer of the non-salt form were found to have R and S configuration, respectively, and the (+)-enantiomer of the magnesium salt and the (−)-enantiomer of the magnesium salt were also found to have R and S configuration, respectively. The conditions for the optical rotation measurement for each of these enantiomers are described in WO 94/27988.
Certain salts of single enantiomers of omeprazole and their preparation are disclosed in WO 94/27988. These compounds have improved pharmacokinetic and metabolic properties which will give an improved therapeutic profile such as a lower degree of interindividual variation.
WO 96/02535 discloses a process for the preparation of the single enantiomers of omeprazole and salts thereof, and WO 96/01623 discloses a suitable tableted dosage forms of for instance magnesium salts of R- and S-omeprazole.


REFERENCES:
patent: 4255431 (1981-03-01), Junggren et al.
patent: 4738974 (1988-04-01), Brandstrom
patent: 4786505 (1988-11-01), Lovgren et al.
patent: 5530160 (1996-06-01), Nore et al.
patent: 5690960 (1997-11-01), Bengtsson et al.
patent: 5693818 (1997-12-01), Von Unge
patent: 5714504 (1998-02-01), Lindberg et al.
patent: 5817338 (1998-10-01), Bergstrand et al.
patent: 5877192 (1999-03-01), Lindberg et al.
patent: 5900424 (1999-05-01), Kallstrom et al.
patent: 1136564 (1996-11-01), None
patent: 0005129 (1979-10-01), None
patent: 0124495 (1984-11-01), None
patent: 0247983 (1987-12-01), None
patent: 9427988 (1994-12-01), None
patent: 9501977 (1995-01-01), None
patent: 9601623 (1996-01-01), None
patent: 9602535 (1996-02-01), None
Erlandson, P. et al., “Resolution of the enantiomers of omeprazole and some of its analogues by liquid chromatography on a trisphenylcarbamoyl cellulose-based stationary phase”, Journal of Chromatography, 532 (1990) 305-319.
von Unge, S. et al. “Stereochemical assignment of the enantiomers of omeprazole from X-ray analysis of a fenchyloxylmethyl derivative (+)-(R)-omeprazole”,Tetrahedron Asymmetry, vol. 8, No. 12, pp. 1967-1970 (1997).
Japanese Chemical Society, Experimental Chemical Seminar. vol. 18. p. 55 (translation), 1958.

Affiliated with

Also associated with

Rating

Potassium salt of S-omeprazole does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Potassium salt of S-omeprazole, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Potassium salt of S-omeprazole will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3221454